MDS Clinical Trials in Houston, Texas
12 recruitingHouston, Texas
Showing 1–12 of 12 trials
Recruiting
Phase 1Phase 2
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Hodgkin LymphomaNon-Hodgkin LymphomaHematologic Malignancies+14 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Beta-ThalassemiaMyelodysplastic Syndromes (MDS)Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Celgene665 enrolled143 locationsNCT04064060
Recruiting
Phase 3
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Myelodysplastic Syndromes (MDS)Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)
Institut de Recherches Internationales Servier48 enrolled62 locationsNCT06465953
Recruiting
Phase 2
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424
Recruiting
Phase 1Phase 2
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Myelodysplastic Syndrome (MDS)Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center40 enrolled1 locationNCT06548230
Recruiting
Phase 1
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)
Cullinan Therapeutics Inc.60 enrolled11 locationsNCT05143996
Recruiting
Phase 1Phase 2
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, RefractoryMDS (Myelodysplastic Syndrome)
ARCE Therapeutics, Inc.49 enrolled3 locationsNCT06680752
Recruiting
Phase 1
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Acute Myeloid LeukemiaMyelodysplastic SyndromesAML/MDS
Montefiore Medical Center38 enrolled2 locationsNCT05986240
Recruiting
Phase 1
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
MDSAML, Adult
Stelexis BioSciences125 enrolled13 locationsNCT06533761
Recruiting
Phase 1
Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)
Smooth Muscle Dysfunction Syndrome (SMDS)
The University of Texas Health Science Center, Houston15 enrolled1 locationNCT06280482
Recruiting
Phase 1
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Hodgkin LymphomaAMLMDS+8 more
Therapeutic Advances in Childhood Leukemia Consortium54 enrolled31 locationsNCT05476770